Table 4.
N | Events | HR (95% CI) | P Value | |
---|---|---|---|---|
All-cause hospitalization | ||||
Baseline PRA (N=356) | ||||
• Non-Black, low PRA | 136 | 41 | REFERENCE | |
• Non-Black, high PRA | 136 | 49 | 1.43 (0.90 – 2.28) | 0.1 |
• Black, low PRA | 40 | 19 | 3.14 (1.68 – 5.87) | <0.001 |
• Black, high PRA | 40 | 20 | 2.08 (1.13 – 3.83) | 0.019 |
72- to 96-hr PRA (N=310) | ||||
• Non-Black, low PRA | 87 | 18 | REFERENCE | |
• Non-Black, high PRA | 88 | 37 | 2.55 (1.55 – 4.20) | <0.001 |
• Black, low PRA | 24 | 10 | 4.51 (2.25 – 9.04) | <0.001 |
• Black, high PRA | 25 | 13 | 3.96 (2.02 – 7.75) | <0.001 |
HF hospitalization | ||||
Baseline PRA (N=356) | ||||
• Non-Black, low PRA | 136 | 24 | REFERENCE | |
• Non-Black, high PRA | 136 | 25 | 1.14 (0.62 – 2.12) | 0.7 |
• Black, low PRA | 40 | 9 | 2.30 (0.98– 5.41) | 0.057 |
• Black, high PRA | 40 | 10 | 1.58 (0.68 – 3.64) | 0.3 |
72- to 96-hr PRA (N=310) | ||||
• Non-Black, low PRA | 87 | 8 | REFERENCE | |
• Non-Black, high PRA | 88 | 19 | 2.00 (1.04 – 3.83) | 0.037 |
• Black, low PRA | 24 | 4 | 2.62 (0.95 – 7.23) | 0.06 |
• Black, high PRA | 25 | 6 | 2.74 (1.09 – 6.94) | 0.033 |
Risk of rehospitalization estimated for subjects enrolled in DOSE-AHF and CARRESS-HF who had measured biomarkers of RAAS activation. PRA was analyzed at baseline for subjects enrolled in DOSE-AHF and CARRESS-HF, and at 72 hr for subjects in DOSE-AHF or 96 hr for subjects in CARRESS-HF. Subjects are classified as high vs. low PRA based on race-specific median values. Models are adjusted for study, age, sex, history of hypertension, blood pressure, HF etiology, ejection fraction, BMI, eGFR, and baseline ACE-I/ARB and aldosterone antagonist use.